An open-label randomised controlled trial evaluating the serogroup B (4CMenB) vaccine on Neisseria gonorrhoea the MenGO study protocol

BMC Public Health

23,

DOI: 10.1186/s12889-023-15516-y

Citation Report

#	Article	IF	CITATIONS
1	Immune responses to Neisseria gonorrhoeae and implications for vaccine development. Frontiers in Immunology, 0, 14, .	4.8	2
3	On The Horizon. Medical Clinics of North America, 2024, 108, 403-418.	2.5	O
4	Evaluating vaccine-elicited antibody activities against <i>Neisseria gonorrhoeae</i> : cross-protective responses elicited by the 4CMenB meningococcal vaccine. Infection and Immunity, 2023, 91, .	2.2	0
5	Promising developments in gonococcal vaccines. Current Opinion in Infectious Diseases, 0, , .	3.1	O
6	<i>Neisseria gonorrhoeae</i> vaccines: a contemporary overview. Clinical Microbiology Reviews, 2024, 37, .	13.6	0